CENTOGENE to Participate in Upcoming Conferences in November
10 nov. 2022 06h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network
03 nov. 2022 06h00 HE
|
Centogene NV
Company’s launch of Biodata Network offers new portfolio of data-driven solutionsCollaboration with BC Platforms increases access to data-driven genomic insights via Global Data Partner Network,...
CENTOGENE to Participate in Upcoming Partnering Conferences in October
06 oct. 2022 06h00 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and...
CENTOGENE Reaches 12,500 Patient Milestone in World’s Largest Observational Study on Parkinson’s Disease Genetics
03 oct. 2022 08h00 HE
|
Centogene NV
Working together with Denali Therapeutics to accelerate data-driven precision medicine for the PD community Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics...
CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September
01 sept. 2022 06h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and...
CENTOGENE Reports First Quarter 2022 Financial Results
15 juil. 2022 08h15 HE
|
Centogene NV
On Track for FY 2022 Guidance Q1 2022 revenue rises 3% to €10.3 million Completed phase out of COVID-19 Business segment in Q1 2022Positioning Pharma and Diagnostics for post-COVID recovery and...
CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer
27 juin 2022 16h01 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and...
CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting
27 juin 2022 16h01 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and...
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
13 juin 2022 06h30 HE
|
Centogene NV
Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic testing and Biodatabank identify causative mutations, including the UGT1A1 and PKLR genes, and...
CENTOGENE’s CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework
25 mai 2022 06h30 HE
|
Centogene NV
CentoCloud, CENTOGENE’s cloud-based Software as a Service (SaaS) platform, is CE-marked under the In Vitro Diagnostics Directive (98/79/EC)CE-marking is required for all in vitro diagnostic (IVD)...